Back to top
more

Cytokinetics (CYTK)

(Delayed Data from NSDQ)

$65.34 USD

65.34
734,584

+0.54 (0.83%)

Updated Apr 26, 2024 04:00 PM ET

After-Market: $65.32 -0.02 (-0.03%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value D Growth B Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 30% (76 out of 252)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Brokerage Reports

Research for CYTK

The Zacks Equity Research reports, or ZER for short, are our in-house, independently produced research reports.

The ever popular one-page Snapshot reports are generated for virtually every single Zacks Ranked stock. It's packed with all of the company's key stats and salient decision making information. Including the Zacks Rank, Zacks Industry Rank, Style Scores, the Price, Consensus & Surprise chart, graphical estimate analysis and how a stocks stacks up to its peers.

The detailed multi-page Analyst report does an even deeper dive on the company's vital statistics. In addition to all of the proprietary analysis in the Snapshot, the report also visually displays the four components of the Zacks Rank (Agreement, Magnitude, Upside and Surprise); provides a comprehensive overview of the company business drivers, complete with earnings and sales charts; a recap of their last earnings report; and a bulleted list of reasons to buy or sell the stock. It also includes an industry comparison table to see how your stock compares to its expanded industry, and the S&P 500.

Researching stocks has never been so easy or insightful as with the ZER Analyst and Snapshot reports.

Learn more about Zacks Equity Research reports

See more Zacks Equity Research reports

 

0 items in cart

Cytokinetics, Incorporated [CYTK]

Reports for Purchase

Showing records 41 - 60 ( 304 total )

Company: Cytokinetics, Incorporated

Industry: Medical - Biomedical and Genetics

Record: 41

02/04/2022

Daily Note

Pages: 5

Omecamtiv Marches Steadily Toward Potential FDA Approval; PDUFA Set for November 30, 2022

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 5.00

Research Provided by a Third Party

Company: Cytokinetics, Incorporated

Industry: Medical - Biomedical and Genetics

Record: 42

02/01/2022

Daily Note

Pages: 5

Aficamten Expands Positive Safety and Efficacy to Harder-to-Treat oHCM Patients

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 5.00

Research Provided by a Third Party

Company: Cytokinetics, Incorporated

Industry: Medical - Biomedical and Genetics

Record: 43

01/07/2022

Company Report

Pages: 8

Cardiac Pipeline Continues to Deliver Solid Deals Ahead of Key Milestones

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 12.50

Research Provided by a Third Party

Company: Cytokinetics, Incorporated

Industry: Medical - Biomedical and Genetics

Record: 44

12/20/2021

Company Report

Pages: 7

Omecamtiv Partners Up For Commercialization in Greater China; Target Upped to $69

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 12.50

Research Provided by a Third Party

Company: Cytokinetics, Incorporated

Industry: Medical - Biomedical and Genetics

Record: 45

12/09/2021

Daily Note

Pages: 5

Aficamten Shifts to Higher Gear in oHCM With Breakthrough Therapy Designation; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 5.00

Research Provided by a Third Party

Company: Cytokinetics, Incorporated

Industry: Medical - Biomedical and Genetics

Record: 46

11/19/2021

Daily Note

Pages: 5

Mavacamten''s PDUFA Postponed as REMS Discussions Deepen; Aficamten Continues to Rise to Top

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 5.00

Research Provided by a Third Party

Company: Cytokinetics, Incorporated

Industry: Medical - Biomedical and Genetics

Record: 47

11/04/2021

Company Report

Pages: 8

3Q21 Results; Major Execution Phase Underway Across Pipeline; Target Increased to $62

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 12.50

Research Provided by a Third Party

Company: Cytokinetics, Incorporated

Industry: Medical - Biomedical and Genetics

Record: 48

10/08/2021

Company Report

Pages: 8

Important Inflection Points Shortly for Differentiated Assets; Investor Day Takeaways

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 12.50

Research Provided by a Third Party

Company: Cytokinetics, Incorporated

Industry: Medical - Biomedical and Genetics

Record: 49

09/28/2021

Company Report

Pages: 10

ValuEngine Detailed Valuation Report for CYTK

Provider: ValuEngine, Inc

Analyst: Research Department

Price: 25.00

Research Provided by a Third Party

Company: Cytokinetics, Incorporated

Industry: Medical - Biomedical and Genetics

Record: 50

09/13/2021

Company Report

Pages: 9

Aficamten Reinforces Its Competitive Profile at HFSA; Omecamtiv Solidifies its NDA Sumbission

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 25.00

Research Provided by a Third Party

Company: Cytokinetics, Incorporated

Industry: Medical - Biomedical and Genetics

Record: 51

08/06/2021

Company Report

Pages: 7

2Q21 Results; Late Stage Pipeline Progresses Towards Value Drivers

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 25.00

Research Provided by a Third Party

Company: Cytokinetics, Incorporated

Industry: Medical - Biomedical and Genetics

Record: 52

08/03/2021

Company Report

Pages: 7

Reldesemtiv Returns to the Clinic With COURAGE; Financials Strengthen Thriving Pipeline

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 25.00

Research Provided by a Third Party

Company: Cytokinetics, Incorporated

Industry: Medical - Biomedical and Genetics

Record: 53

07/19/2021

Company Report

Pages: 8

Strong Bough from REDWOOD-HCM; ''274 Data Impress With Pivotal Start Looming

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 25.00

Research Provided by a Third Party

Company: Cytokinetics, Incorporated

Industry: Medical - Biomedical and Genetics

Record: 54

06/30/2021

Company Report

Pages: 7

Omecamtiv Strengthens Its Position in HF Ahead of NDA Submission in 2H21

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 25.00

Research Provided by a Third Party

Company: Cytokinetics, Incorporated

Industry: Medical - Biomedical and Genetics

Record: 55

06/28/2021

Company Report

Pages: 7

KOLs’ Perspective on Cardiac Myosin Inhibitors in oHCM; All Eyes on REDWOOD-HCM Imminent Data

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 25.00

Research Provided by a Third Party

Company: Cytokinetics, Incorporated

Industry: Medical - Biomedical and Genetics

Record: 56

05/18/2021

Company Report

Pages: 8

Omecamtiv Gains the Spotlight Among Therapies For Patients With Severe HF at ACC.21; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 25.00

Research Provided by a Third Party

Company: Cytokinetics, Incorporated

Industry: Medical - Biomedical and Genetics

Record: 57

05/07/2021

Company Report

Pages: 8

Key Progress Across All Programs Sets Milestones for 2H21; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 25.00

Research Provided by a Third Party

Company: Cytokinetics, Incorporated

Industry: Medical - Biomedical and Genetics

Record: 58

05/04/2021

Daily Note

Pages: 5

REDWOOD-HCM Expands With Cohort 3; All Eyes on CK-274''s Results in Mid-2021

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 10.00

Research Provided by a Third Party

Company: Cytokinetics, Incorporated

Industry: Medical - Biomedical and Genetics

Record: 59

04/12/2021

Daily Note

Pages: 5

CK-274’s Promising PK/PD Profile Emerges at ASC’21 With Key Differentiation to Comps

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 10.00

Research Provided by a Third Party

Company: Cytokinetics, Incorporated

Industry: Medical - Biomedical and Genetics

Record: 60

02/26/2021

Company Report

Pages: 7

2020 Results; Critical Visibility from FDA Soon for Omecamtiv; CK-274 Should Continue to Differentiate in 2021

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 25.00

Research Provided by a Third Party